6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer
Open Access
- 29 October 2013
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 4 (11) , 2124-2134
Abstract
Genetic and epigenetic alterations have been identified as to contribute directly or indirectly to the generation of transitional cell carcinoma of the urinary bladder (TCC-UB). In a comparative fashion much less is known about copy number alterations in TCC-UB, but it appears that amplification of chromosome 6p22 is one of the most frequent changes. Using fluorescence in situ hybridization (FISH) analyses, we evaluated chromosomal 6p22 amplification in a large cohort of bladder cancer patients with complete surgical staging and outcome data. We have also used shRNA knockdown candidate oncogenes in the cell based study. We found that amplification of chromosome 6p22.3 is significantly associated with the muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) (22%) in contrast to superficial TCC-UB (9%) (p=7.2-04). The rate of 6p22.3 amplification in pN>1 patients (32%) is more than twice that in pN0 (16%) patients (p=0.05). Interestingly, we found that 6p22.3 amplification is as twice as high (p=0.0201) in African American (AA) than European American (EA) TCC-UB patients. Moreover, we showed that the expression of some candidate genes (E2F3, CDKAL1 and Sox4) in the 6p22.3 region is highly correlated with the chromosomal amplification. In particular, knockdown of E2F3 inhibits cell proliferation in a 6p22.3-dependent manner, whereas knockdown of CDKAL1 and Sox4 has no effect on cell proliferation. Using gene expression profiling, we further identified some common as well as distinctive subset targets of the E2F3 family members. In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.Keywords
This publication has 32 references indexed in Scilit:
- SOX4 Induces Epithelial–Mesenchymal Transition and Contributes to Breast Cancer ProgressionCancer Research, 2012
- Bioconductor: open software development for computational biology and bioinformaticsGenome Biology, 2004
- E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancerOncogene, 2004
- Gender, racial and age differences in bladder cancer incidence and mortalityUrologic Oncology: Seminars and Original Investigations, 2004
- FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.2003
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Sibling rivalry in the E2F familyNature Reviews Molecular Cell Biology, 2002
- Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines.2000
- Identification of a Novel E2F3 Product Suggests a Mechanism for Determining Specificity of Repression by Rb ProteinsMolecular and Cellular Biology, 2000
- Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder CancerJNCI: Journal of the National Cancer Institute, 1992